104 recruiting. 104 Phase 2, 13 Phase 1, 11 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 104 | Recruiting 104 |
| Phase 1 | 13 | Recruiting 13 |
| Phase 3 | 11 | Recruiting 11 |
Follow Behavioral Symptoms: new trials by email Literature Review of Behavioral Symptoms trials Research Report on Behavioral Symptoms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS - Treatment Resistant Depression, Treatment Resistant Depression (TRD) | Phase 2 / Phase 3 | Recruiting | NeuroRx, Inc. | 240 | 2026-12-01 | 2026-10-21 |
| A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety CYB003, Placebo - Depression, Anxiety | Phase 2 | Recruiting | Ohio State University | 40 | 2026-11-01 | 2026-10-20 |
| JAK Signaling in Depression and Cognition in Male Football Players Baricitinib - Depressive Symptoms, Cognitive Symptom | Phase 2 | Recruiting | Emory University | 30 | 2026-10-01 | 2026-09-24 |
| Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department Ketamine Injectable Solution, Placebo Injection, Crisis Response Plan - Suicidal Ideation | Phase 2 | Recruiting | The University of Texas Health Science Center at San Antonio | 200 | 2026-09-30 | 2026-10-15 |
| HBOT Effects on First Responders' Cognition and Well-Being Hyperbaric Oxygen Therapy (HBOT) - Traumatic Brain Injury, PTSD - Post Traumatic Stress Disorder | Phase 2 | Recruiting | Summit Hyperbarics and Wellness | 54 | 2026-09-11 | 2026-10-01 |
| Precision Depression Adalimumab Trial Adalimumab Biosimilars Injection, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Daniel Moriarity | 60 | 2026-09-01 | 2026-09-29 |
| Psilocybin-Assisted Therapy for Intergenerational Trauma Psilocybin, Integration sessions - Psychological Stress, Depression | Phase 2 | Recruiting | Rachel Yehuda | 100 | 2026-08-28 | 2026-08-13 |
| Caring Recharge Project for Caregivers of Individuals With Alzheimer's Disease Recharge Behavioral Therapy, Traditional Educational/Resources Program - Caregiver Stress | Phase 2 | Recruiting | Photozig, Inc. | 150 | 2026-08-14 | 2026-08-21 |
| Psilocybin to Treat Depression in Spinal Cord Injury Psilocybin (Usona Institute) - Spinal Cord Injury, Depression - Major Depressive Disorder | Phase 1 / Phase 2 | Recruiting | James J. Peters Veterans Affairs Medical Center | 30 | 2026-08-06 | 2026-08-10 |
| Inhaled DMT for Major Depressive Disorder N,N-Dimethyltryptamine (15 mg + 60 mg), N,N-Dimethyltryptamine (1 mg + 4 mg) - MDD, Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Universidade Federal do Rio Grande do Norte | 140 | 2026-08-01 | 2026-07-13 |
| Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) Ketamine Hydrochloride, Midazolam Hydrochloride, Dialectical Behavioral Therapy (DBT) - Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder | Phase 2 | Recruiting | Joshua Rosenblat | 120 | 2026-07-16 | 2026-07-29 |
| The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease Psilocybin (drug) - Depression, Parkinson's Disease (PD) | Phase 2 | Recruiting | Yale University | 40 | 2026-07-10 | 2026-09-28 |
| A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) TNX-102 SL, Placebo sublingual tablet - Major Depressive Episode (MDE), Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Tonix Pharmaceuticals, Inc. | 360 | 2026-06-25 | 2026-09-25 |
| Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder psilocybin (25 mg), psilocybin 1mg micro-dose - Bipolar II Depression | Phase 2 | Recruiting | Lakshmi N Yatham | 90 | 2026-06-15 | 2026-09-15 |
| Allopurinol in Depression Sertraline 50 MG, Allopurinol 300 MG - Depression | Phase 2 / Phase 3 | Recruiting | Tanta University | 70 | 2026-05-20 | 2026-08-18 |
| Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID Paragon Novel Metabolic Regulator (PNMR), Dietary and Lifestyle Recommendations - Long COVID | Phase 2 | Recruiting | ParagonClinicals Inc. | 82 | 2026-05-20 | 2026-06-04 |
| Evaluating the Effectiveness of the Common Elements Treatment Approach (CETA) in Peru: Mechanisms of Individual and Intergenerational Change Common Elements Treatment Approach, Enhanced Case Managment - Violence, Parenting | Phase 2 | Recruiting | University of Notre Dame | 600 | 2026-05-18 | 2026-06-25 |
| A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression DT-101, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Draig Therapeutics Ltd | 118 | 2026-05-14 | 2026-10-14 |
| Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients Ketamine (0.5 mg/kg), Normal Saline (0.9% NaCl) - Critical Illness, Depressive Symptoms | Phase 2 | Recruiting | Hospital Italiano de Buenos Aires | 50 | 2026-05-14 | 2026-09-02 |
| Mindfulness Engaged Neurostimulation for Depression (MEND II) Medi-TBS - Depression, Treatment Resistant Depression | Phase 2 | Recruiting | University of California, San Diego | 120 | 2026-05-01 | 2026-05-06 |
Showing 20 of 104. Sign in to see all of them.
Depression (78) · Depressive Disorder, Major (25) · Anxiety Disorders (24) · Suicidal Ideation (11) · Suicide (10) · Depressive Disorder (8) · Depressive Disorder, Treatment-Resistant (7) · Aggression (6) · Bipolar Disorder (5) · Inflammation (5) · Mental Disorders (5) · Mood Disorders (5) · Pain (5) · Stress Disorders, Post-Traumatic (5) · Alzheimer Disease (4)
Behavior (102) · Mental Disorders (59) · Pathological Conditions, Signs and Symptoms (33) · Mood Disorders (25) · Nervous System Diseases (25) · Signs and Symptoms (24) · Neurologic Manifestations (22) · Depressive Disorder (20) · Self-Injurious Behavior (16) · Central Nervous System Diseases (15) · Pathologic Processes (14) · Brain Diseases (12) · Neurobehavioral Manifestations (10) · Neurodegenerative Diseases (9)
Psilocybin (14) · Ketamine (9) · Fluoxetine (3) · Oxygen (3) · Sertraline (3) · Exercise (2) · Injections (2) · Midazolam (2) · N,N-Dimethyltryptamine (2) · Pregnenolone (2) · Sodium Chloride (2) · Transcranial Magnetic Stimulation (2) · baricitinib (2) · pimavanserin (2) · 3-(3-(methylsulfonyl)phenyl)-1-propylpiperidine (1)
VA Office of Research and Development (4) · Ohio State University (3) · University of California, Los Angeles (3) · University of California, San Diego (3) · Bernardino Clavo, MD, PhD (2) · Draig Therapeutics Ltd (2) · Emory University (2) · M.D. Anderson Cancer Center (2) · Massachusetts General Hospital (2) · National Institute of Mental Health (NIMH) (2) · Tanta University (2) · The University of Texas Health Science Center at San Antonio (2) · University of Colorado, Boulder (2) · Washington University School of Medicine (2) · Yale University (2)
United States (75) · Canada (11) · Czechia (5) · Poland (5) · Bulgaria (4) · Spain (4) · Switzerland (4) · Argentina (3) · Brazil (3) · France (3) · United Kingdom (3) · Australia (2) · Chile (2) · China (2) · Denmark (2)
Andrew H Miller, MD (2) · Bernardino Clavo, MD, PhD (2) · Carlos A Zarate, M.D. (2) · Abhishek Jaywant, PhD (1) · Alan Peterson, PhD, ABPP (1) · Alexander McGirr, MD PhD (1) · Andreas Reif, Prof. Dr. med. (1) · Andreas W Blomkvist, M.D. (1) · Ben Palanca, MD PhD (1) · Bernard Baumel, MD (1) · Bradley J MacIntosh, PhD (1)
PMID 20717121, PMID 27210031, PMID 27909164, PMID 31060042, PMID 31636488, PMID 32757505, PMID 33146667, PMID 36322843, PMID 37651119, PMID 37891522, PMID 37997749, PMID 38874947, PMID 38956594, PMID 39260823, PMID 39760650, PMID 40297050, PMID 40669910, PMID 40887012, PMID 40990413, PMID 41019467, PMID 41555748, PMID 41572235, PMID 41593831, PMID 41622533, PMID 41956449, PMID 42171126, PMID 42245142, PMID 42284615, PMID 42442821, PMID 42808010
2023 (4), 2025 (1), I01CX002583 (1), I01RX004287 (1), IK2CX002646-01A2 (1), K23MH129849 (1), R01HD108133 (1), R01HD116815 (1), R01MH128872 (1), R01MH131194 (1), R01MH133925 (1), R44AG084419 (1), R61MH133770 (1), U01MH128483 (1), UL1TR002645 (1)